IGC Pharma (IGC) Operating Leases (2020 - 2025)

IGC Pharma (IGC) has reported Operating Leases for 6 consecutive years, with $2000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Operating Leases fell 83.33% year-over-year to $2000.0 in Q4 2025; TTM through Dec 2025 was $2000.0, a 83.33% decrease from a year earlier, with the FY2025 full-year figure at $10000.0, down 95.19% from the prior year.
• Operating Leases was $2000.0 for Q4 2025 at IGC Pharma, down from $5000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $433000.0 in Q2 2021 and troughed at $2000.0 in Q4 2025.
• A 5-year average of $195450.0 and a median of $193500.0 in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases retreated 0.29% in 2023 and tumbled 95.19% in 2025, its largest moves.
• Over 5 years, Operating Leases stood at $374000.0 in 2021, then sank by 35.56% to $241000.0 in 2022, then slumped by 52.28% to $115000.0 in 2023, then slumped by 89.57% to $12000.0 in 2024, then plunged by 83.33% to $2000.0 in 2025.
• The last three Operating Leases figures came in at $2000.0 (Q4 2025), $5000.0 (Q3 2025), and $7000.0 (Q2 2025), per Business Quant data.